ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 0395 • ACR Convergence 2022

    How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study

    Uta Kiltz1, Jan Brandt-Juergens2, Peter Kästner3, Elke Riechers4, Daniel Peterlik5, Christina Budden5 and Hans-Peter Tony6, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumatologische Schwerpunktpraxis, Berlin, Germany, 3Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, 4Medizinische Hochschule Hannover, Hannover, Germany, 5Novartis Pharma GmbH, Nürnberg, Germany, 6Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany

    Background/Purpose: There is a higher prevalence of obesity in patients (pts) with psoriatic disease1. The German non-interventional study AQUILA provides real-world data on the influence…
  • Abstract Number: 0855 • ACR Convergence 2022

    Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Melissa Mannion1, Fenglong Xie1, Timothy Beukelman1, Jeffrey Curtis2 and , for the CARRA Registry Investigators3, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Hoover, AL, 3CARRA, Washington, DC

    Background/Purpose: Current recommendations suggest treatment escalation for juvenile idiopathic arthritis (JIA) until the disease activity target is reached, ideally inactive or low disease activity. Our…
  • Abstract Number: 1026 • ACR Convergence 2022

    Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis

    Paras Karmacharya1, Courtney Stull2, Alisa Stephens-Shields3, M. Elaine Husni4, Jose Scher5, Ethan Craig6, Robert Fitzsimmons3, Soumya Reddy7, Marina Magrey8, Alexis Ogdie9 and Jessica Walsh10, 1Vanderbilt University, Nashville, TN, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pennsylvania, Philadelphia, 4Cleveland Clinic, Cleveland, OH, 5New York University School of Medicine, New York, NY, 6University of Pennsylvania, Wallingford, PA, 7NYU School of Medicine, New York, NY, 8Case Western Reserve University, University Hospitals, Richfield, OH, 9Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 10University of Utah, Salt Lake City, UT

    Background/Purpose: Despite significant heterogeneity in psoriatic arthritis (PsA), randomized controlled trials (RCTs) generally enroll a homogenous subgroup of PsA patients (polyarticular similar to rheumatoid arthritis).…
  • Abstract Number: 1392 • ACR Convergence 2022

    Comparing Data on Rheumatoid Arthritis (RA) Disease Status Using Patient Reported Outcome Measures (PROMS) RAID/RAPID-3/Self-Reported DAS28 in Remote Electronic Monitoring During the COVID-19 Pandemic with Face-To-Face Clinical Evaluation (DAS28-CRP) Performed Pre-Pandemic

    Maria Mirza1, Kaiyang Song1, Madiha Ashraf2, Anushka Soni3, John Jackman3 and Raashid Luqmani1, 1Oxford University Hospital, Oxford, United Kingdom, 2Oxford Universtiy Hospital, Oxford, United Kingdom, 3Oxford University Hospital, Oxford, England, United Kingdom

    Background/Purpose: During the COVID-19 pandemic, asynchronous consultations were introduced due to the significant backlog of patients with Rheumatoid arthritis awaiting clinical review. PROMs including Self-Reported…
  • Abstract Number: 1516 • ACR Convergence 2022

    How Disease Activity Can Affect Workability in Spondyloarthropaties: A Monocentric Cohort Analysis

    Federico Fattorini1, Cosimo Cigolini2, Gabriele Marchetti3, Andrea Delle Sedie4, Linda Carli5 and Marta Mosca5, 1Rheumatology Unit, University of Pisa, Pisa, Italy, 2Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, 3University of Pisa, Pisa, Toscana, Italy, 4University of Pisa, Pisa, Pisa, Italy, 5Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, PISA, Italy

    Background/Purpose: Spondyloarthropathies (SpA) may compromise the working ability (WA) of patients, often affected by the disease during their productive life. The Work Productivity and Activity…
  • Abstract Number: 1971 • ACR Convergence 2022

    Cumulative Joint Inflammation Is Associated with Local Joint Damage Progression in Rheumatoid Arthritis Despite Long-Term Targeted Treatment

    Sascha Heckert1, Sytske Anne Bergstra2, Yvonne Goekoop-Ruiterman3, Melek Guler-Yuksel4, Willem Lems5, Xanthe Matthijssen6, Maikel Van Oosterhout7, Tom Huizinga6 and CF Allaart6, 1Leiden University Medical Centre, Leiden, Netherlands, 2LUMC, Leiden, Netherlands, 3HagaZiekenhuis, The Hague, Netherlands, 4Maasstad ziekenhuis, Rotterdam, Netherlands, 5Amsterdam University Medical Centers, Amsterdam, Netherlands, 6Leiden University Medical Center, Leiden, Netherlands, 7Groene Hart Ziekenhuis, Gouda, Netherlands

    Background/Purpose: In Rheumatoid Arthritis (RA), both systemic and local disease activity have been shown to be associated with joint damage progression. Earlier we showed that…
  • Abstract Number: 2096 • ACR Convergence 2022

    Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus

    Marcela Muñoz Urbano1, Diana C. Quintero-González1, Mauricio Rojas2, Joaquín Rodelo1, Alba Luz León Álvarez1, Luis Gonzalez1 and Gloria Vásquez3, 1Universidad de Antioquia, Medellín, Colombia, 2Grupo de Inmunología Celular e Inmunogenética, GICIG, and Unidad de citometría de flujo, Sede de Investigación Universitaria, Universidad de Antioquia, Medellín, Colombia, 3Grupo de Inmunología Celular e Inmunogenética, GICIG and Grupo de Reumatología, Universidad de Antioquía, Medellín, Colombia

    Background/Purpose: The prompt identification of patients with systemic lupus erythematosus (SLE) at risk of or in flare strongly influences the prognosis of the disease. Cell-bound…
  • Abstract Number: 0173 • ACR Convergence 2022

    Cutaneous Manifestations, Clinical Trials, Safety Efficacy and Safety of Lenabasum in the Phase 3 DeterMine Trial in Dermatomyositis

    Victoria Werth1, Barbara White2, Josef Concha3, Josh Dan1, Nancy Dgetluck2, Kathleen Hally2, Scott Constantine2, Rohit Aggarwal4, David Fiorentino5, Ingrid Lundberg6 and Chester Oddis7, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 2Corbus Pharmaceuticals, Norwood, MA, 3Universiity of Pennsylvania/Dermatology, Philadelphia, PA, 4University of Pittsburgh, Division of Rheumatology, Pittsburgh, PA, 5Stanford university/Department of Dermatology, Palo Alto, CA, 6Karolinska Institute, Stockholm, Sweden, 7University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Safe and effective treatments are of significant unmet need in DM. Lenabasum, a CB2 agonist that activates resolution of inflammation, improved skin disease, patient-reported…
  • Abstract Number: 0421 • ACR Convergence 2022

    Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Prior bDMARD Treatment: Analysis of a Phase 3 Trial

    Atul Deodhar1, Helena Marzo-Ortega2, Joseph Wu3, Cunshan Wang3, Oluwaseyi Dina4, Keith S Kanik3, Lara Fallon5 and Lianne Gensler6, 1Oregon Health & Science University, Portland, OR, USA, Portland, OR, 2Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, 3Pfizer Inc, Groton, CT, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Montréal, QC, Canada, 6Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Prior exposure to biologic (b)DMARD therapy of patients (pts) with AS may influence treatment response.1-3 Tofacitinib is an oral JAK inhibitor for the treatment…
  • Abstract Number: 0858 • ACR Convergence 2022

    Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis

    Melissa Mannion1, Chen Chen2, Olha Halyabar3, Susan Paetkau4, Tingting Qiu5 and Bin Huang6, 1University of Alabama at Birmingham, Birmingham, AL, 2Cincinnati Children's Hospital Medical Center, Taipei, Taiwan, 3Children's Hospital/Boston Medical Center, Boston, MA, 4The Hospital for Sick Children, Toronto, ON, Canada, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Cincinnati Children's Hospital Medical Center, Cinciannati, OH

    Background/Purpose: The goal of treatment for juvenile idiopathic arthritis (JIA) is inactive disease (ID), but the optimal treatment for each patient to maximize ID and…
  • Abstract Number: 1033 • ACR Convergence 2022

    Risk of Mood Disorders in SpA Patients and Correlations with Disease Activity, Quality of Life and Working Ability: Analysis of a Monocentric Cohort

    Cosimo Cigolini1, Federico Fattorini1, Linda Carli2, Andrea Delle Sedie3, Marta Mosca2 and Gabriele Marchetti4, 1Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, PISA, Italy, 3University of Pisa, Pisa, Pisa, Italy, 4University of Pisa, Pisa, Toscana, Italy

    Background/Purpose: Spondyloarthropathies (SpA) are chronic inflammatory arthritides, characterized by both peripheral and axial skeletal involvement and some typical extra-articular marks; they tend to associate with…
  • Abstract Number: 1401 • ACR Convergence 2022

    Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study

    George A Karpouzas1, Zoltan Szekanecz2, Eva Baecklund3, Ted Mikuls4, Deepak L Bhatt5, Harry Shi6, Cunshan Wang7, Gosford A Sawyerr8, Yan Chen6, Sujatha Menon7, Carol A Connell7, Steven R Ytterberg9 and Mahta Mortezavi8, 1Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, 2Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary, 3Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 4Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5Department of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 6Pfizer, Inc, Collegeville, PA, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, New York, NY, 9Division of Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Uncontrolled RA activity and acute disease flares are associated with higher risk of adverse outcomes, such as cardiovascular (CV) disease, venous thromboembolism (VTE), malignancy,…
  • Abstract Number: 1544 • ACR Convergence 2022

    Is It Possible to Evaluate Polymyalgia Rheumatica Without C-reactive Protein? Concordance and Agreement Between Different PMR Activity Scores in Polymyalgia Rheumatica

    Justine D'agostino1, Valerie Devauchelle1, Guillermo CARVAJAL ALEGRIA2, Emmanuelle Dernis3, Christophe Richez4, Marie Truchetet5, Daniel Wendling6, ERIC TOUSSIROT7, aleth Perdriger8, jacques-eric gottenberg9, Renaud FELTEN10, Bruno Fautrel11, laurent chiche12, Pascal HILLIQUIN13, Catherine Le Henaff14, Benjamin Dervieux15, Guillaume Direz16, Isabelle Chary-Valckenaere17, Divi CORNEC18, Dewi Guellec19, Thierry MARHADOUR20, Aghiles Souki19, Emmanule Nowak19 and Alain Saraux21, 1Université de Bretagne Occidentale, Brest, France, 2CHRU de Tours, Tours, France, 3LE MANS general hospital, LE MANS, France, 4Université de Bordeaux, Bordeaux, France, 5Bordeaux University Hospital, Bordeaux, France, 6CHU, University Teaching Hospital, Besançon, France, 7CHU de Besançon, Besançon, France, 8Rennes University, Rennes, France, 9Strasbourg University Hospital, Strasbourg, France, 10Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 11Pitié Salpêtrière Hospital, Paris, France, 12hopital europeen, Marseille, France, 13Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France, 14Morlaix Hospital, Morlaix, France, 15Mulhouse Hospital, Mulhouse, France, 16Le Mans Hospital, Le Mans, France, 17Nancy University Hospital, Vandoeuvre, France, 18CHRU Brest, Brest, France, 19Brest University Hospital, Brest, France, 20CHU Cavale Blanche, Brest, France, 21CHU Brest, Brest, France

    Background/Purpose: Today, the only disease activity score developed specifically for polymylagia rheumatica is the PMR-AS. It is a composite index built as an algebraic sum…
  • Abstract Number: 1986 • ACR Convergence 2022

    Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment

    Sofie Falkenløve Madsen1, Dovile Sinkeviciute2, Christian Thudium2, Morten Karsdal2 and Anne-Christine Bay-Jensen2, 1University of Copenhagen / Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, autoimmune disease, which normally is characterized by inflammation and thickening of the synovial membrane leading to swollen and…
  • Abstract Number: 2109 • ACR Convergence 2022

    Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Arthur Kavanaugh1, Gordon Lam2, Lai-shan Tam3, Natalie Shiff4, Youngja Lee5, Ana-Maria Bravo Perdomo6, May Shawi7, Elizabeth Hsia8, Emmanouil Rampakakis9 and Carlos Enrique Toro Gutiérrez10, 1University of California San Diego, La Jolla, CA, 2Arthritis and Osteoporosis Consultants of the Carolinas; Clinical Affiliate, Atrium Health and the Wake Forest School of Medicine, Cornelius, NC, 3The Chinese University of Hong Kong, Hong Kong, China, 4Janssen Scientific Affairs, LLC, Horsham, PA, USA/ Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada, Philadelphia, PA, 5Immunology Medical Affairs, Janssen Asia Pacific, Yongsan-gu, Seoul, Republic of Korea, 6Immunology Medical Affairs, Janssen Latin America, Columbia, Colombia, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Janssen Research and Development, LLC; University of Pennsylvania School of Medicine, Kennett Square, PA, 9McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 10Internal Medicine and Rheumatology, Reference Center for Osteoporosis, Rheumatology & Dermatology. Pontificia Javeriana University, Calí, Colombia

    Background/Purpose: Sustained minimal disease activity (MDA) is only achieved by a small portion of PsA patients (pts). Levels of disease activity consistent with MDA may…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 102
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology